Shanghai Shyndec Pharmaceutical Co., Ltd.

Equities

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-05-21 pm EDT 5-day change 1st Jan Change
11.53 CNY -2.70% Intraday chart for Shanghai Shyndec Pharmaceutical Co., Ltd. -5.49% +17.77%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets MT
China stocks rise after new guidelines; HK shares drop RE
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator MT
Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine MT
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan MT
China Grants Supplementary Drug Approval for Shyndec Pharmaceutical Subsidiaries' Antibiotic, Hypertension Tablets MT
Shyndec Pharma Passes Drug GMP Compliance Inspection MT
Shyndec Pharmaceutical's Drug Chosen for China's Centralized Bid MT
Shyndec Pharmaceutical Unit's Cefprozil Tablets Passes Regulatory Evaluation MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shyndec Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride's Listing MT
Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) added to S&P Global BMI Index CI
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shyndec Pharmaceutical's Unit Gets Nod for Registration of Oprinone Hydrochloride Injection MT
Shanghai Shyndec Pharma Chairman Resigns MT
Shyndec Pharmaceutical Unit's Infection Drug Passes Regulatory Evaluation MT
Shyndec Pharma Unit's Clindamycin Phosphate Injection Passes Regulatory Evaluation MT
Amoxicillin Capsules of Shyndec Pharma's Unit Passes Regulatory Evaluation MT
Chart Shanghai Shyndec Pharmaceutical Co., Ltd.
More charts
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
11.85
Average target price
-
Consensus
  1. Stock Market
  2. Equities
  3. 600420 Stock
  4. News Shanghai Shyndec Pharmaceutical Co., Ltd.
  5. Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW